Cellectis reports Q2 EPS (19c), consensus (45c)

Reports Q2 revenue $5.56M, consensus $4.48M. As of June 30, 2023, Cellectis, had $89M in consolidated cash, cash equivalents, and restricted cash. This compares to $95M in consolidated cash, cash equivalents and restricted cash as of December 31, 2022. “We are proud of our team and the strong execution this quarter. Our clinical data presented for UCART22 at the European Hematology Association were positive for patients with r/r B-ALL who have failed multiple lines of treatment including multi-agent chemoimmunotherapy, CD19 directed CAR T-cell therapy, and allogeneic stem cell transplant. We are looking forward to releasing new data later this year on our UCART22 product candidate manufactured in-house,” said CEO Andre Choulika. “In addition, we have made progress with our pipeline in 2023 and continue to focus on our core clinical trials BALLI-01 (evaluating UCART22), NATHALI-01 (evaluating UCART20x22) and AMELI-01 (evaluating UCART123). This quarter, Cellectis presented an encore of the clinical data on the AMELI-01 clinical trial at the American Society of Gene and Cell Therapy 2023 annual meeting. These preliminary data support the continued administration of UCART123 after FCA lymphodepletion in patients with r/r AML.